Payer Policy

CVS Caremark Prior Authorization Guide 2026: How to Get Specialty Drugs Approved

CVS Caremark manages 100M+ Americans' pharmacy benefits. Step-by-step PA submission, appeal process, clinical criteria, and drug-specific tips for 2026.

RxCheckUp Clinical Team · 2026-07-01 · 14 min read

Who Is CVS Caremark — and Why Does It Matter for Prior Authorization?

CVS Caremark is the largest pharmacy benefit manager (PBM) in the United States by prescription volume, managing pharmacy benefits for more than 100 million Americans across commercial, Medicare Part D, Medicaid managed care, and employer self-funded plans. As the PBM arm of CVS Health — which also owns Aetna — Caremark processes an estimated 2 billion prescriptions per year.

When your patient's insurance card routes through CVS Caremark, every specialty drug prior authorization, formulary exception, and step-therapy override is processed by Caremark's clinical review team. Understanding how Caremark's PA workflow operates — and what clinical language gets approvals — is one of the highest-leverage skills a specialty prescriber can develop.

Importantly, Caremark processes PA for multiple employer and health plan clients, each of which may have its own formulary and criteria on top of Caremark's standard clinical review protocols. This means the same drug may have different criteria on two plans both processed by Caremark. Always pull the specific plan's coverage policy — not just a generic "Caremark" policy.

How to Identify a CVS Caremark PA Request

CVS Caremark prior authorizations are submitted through several channels depending on the drug type and practice setup:

✓ Electronic PA (ePA): Through your EHR's electronic PA integration (most major EHRs including Epic, Cerner, and Athena support Caremark ePA via CoverMyMeds or Surescripts)
✓ CoverMyMeds portal (covermymeds.com): Fastest manual route for most specialty drugs — pre-loaded with Caremark's current criteria fields
✓ Caremark Specialty PA fax line: Drug-specific fax numbers printed on the specialty pharmacy routing sheet; call Caremark Specialty at 1-800-294-5979 to confirm
✓ Phone: Caremark PA line at 1-800-294-5979 (specialty) or the number on the back of the member ID card
✓ Provider portal: specialty.caremark.com — plan-specific login required

CVS Caremark PA Timelines (2026)

Under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), impacted payers must respond to non-urgent PA decisions within 7 calendar days and urgent decisions within 72 hours starting in 2026. Caremark has begun aligning its commercial timelines to these standards ahead of mandatory implementation.

Standard PA timelines for CVS Caremark specialty drugs in 2026:

✓ Urgent (expedited) PA: 24–72 hours
✓ Non-urgent initial PA: 3–7 business days (varies by plan)
✓ PA appeal (internal Level 1): 30–60 days for non-urgent, 72 hours for urgent
✓ PA appeal (external independent review): typically 30–45 days
✓ Step therapy override: same timeline as PA; document medical necessity in the primary request to avoid a separate override submission

The CVS Caremark PA Clinical Review Framework

Caremark clinical reviewers evaluate PA requests against three documents: (1) the plan sponsor's benefit design and formulary, (2) Caremark's own Standard Clinical Review Criteria, and (3) FDA labeling. Understanding all three is necessary to write an approvable PA.

Caremark's Standard Clinical Review criteria are built on the same pillars that all major PBMs use, but with specific documentation thresholds:

✓ Diagnosis confirmation: ICD-10 code must match the drug's FDA indication — use the most specific code available
✓ Step therapy: document every prior agent tried, with start date, stop date, dose, and reason for discontinuation; "inadequate response" is not sufficient — quantify the response failure (e.g., "PHQ-9 decreased from 22 to 18 after 12 weeks of sertraline 200mg — inadequate by <50% improvement criterion")
✓ Lab or imaging evidence: required for many high-spend drugs — e.g., A1c for GLP-1 diabetes, PASI/EASI for biologics, echocardiogram for mavacamten, flow cytometry for oncology hematologics
✓ Prescriber specialty: some plans require specialist initiation (e.g., rheumatologist for TNF inhibitors, oncologist for cancer drugs); document your specialty and any co-management
✓ Quantity limits: standard doses must be requested; document clinical rationale for any quantity above the label starting dose

CVS Caremark Step Therapy: What You Need to Know

Step therapy (also called "fail first") is CVS Caremark's most common cause of first-pass specialty PA denials. Caremark's step-therapy protocols are plan-specific, but several patterns appear across the majority of commercial plans:

✓ Biologics (RA, PsA, IBD, AS): methotrexate or other csDMARDs required before most biologic DMARDs; for IBD, 5-ASA or immunomodulator required first
✓ GLP-1s for obesity (Wegovy, Zepbound): ≥1–2 prior weight-loss agents required (phentermine, orlistat, Contrave); behavioral program documentation required
✓ IL-17/IL-23 inhibitors (Cosentyx, Skyrizi, Taltz, Tremfya): prior TNF inhibitor failure or contraindication commonly required
✓ Atopic dermatitis biologics (Dupixent, Ebglyss): topical corticosteroids + topical calcineurin inhibitor required first; some plans require Dupixent trial before Ebglyss or Adbry
✓ Oncology: step therapy is rarely applied for FDA-indicated uses — but payers may require biomarker testing results (e.g., EGFR, ALK, KRAS, PD-L1) before approving targeted agents
✓ Overcoming step therapy: document contraindication, intolerance (with clinical details), or step agent failure — a blanket "not effective" without specific details will result in denial

CVS Caremark Formulary Exception Process

When a drug is on a non-preferred tier or requires a formulary exception, the exception process is separate from (but often combined with) the PA request. Caremark's formulary exception criteria require clinical justification that the requested drug is medically necessary and that the formulary alternative is not appropriate.

Three grounds for a formulary exception at Caremark:

✓ 1. Formulary alternative is contraindicated: cite the specific contraindication with supporting documentation (allergy, drug interaction, comorbidity that precludes use)
✓ 2. Formulary alternative was tried and failed: document the trial (dates, dose, duration) and the nature of failure (adverse effect or inadequate response)
✓ 3. Formulary alternative is expected to fail based on patient-specific clinical factors: this is the most discretionary and requires the strongest clinical justification — cite peer-reviewed literature or guideline recommendations specific to the patient's clinical features

Drug-Specific CVS Caremark PA Tips (High-Volume Specialty Drugs)

The following drugs are among the most frequently prior-authorized through CVS Caremark, with the most common denial reason and the documentation fix:

✓ Humira/adalimumab biosimilars: Caremark formularies increasingly prefer biosimilars (Amjevita, Hadlima, Cyltezo) — if requesting originator adalimumab, provide clinical rationale for the specific formulation; biosimilar PA is usually streamlined
✓ Dupixent (dupilumab): EASI or IGA score required for AD; spirometry and eosinophil count for asthma; nasal polyp endoscopy report for CRSwNP — attach the specific objective measure for the indication being requested
✓ Ozempic/Mounjaro (T2DM): A1c ≥7.0% and documentation of metformin use (or intolerance) required; include most recent A1c with lab date
✓ Wegovy/Zepbound (obesity): BMI ≥30 (or ≥27 + comorbidity) with in-clinic measurement within 60 days; 6-month lifestyle program documentation; 1–2 prior weight-loss agent trials
✓ Keytruda (pembrolizumab): include PD-L1 TPS or CPS score, tumor histology, line of therapy, and ECOG PS — missing any one element triggers information request delays
✓ Rinvoq/Xeljanz (JAK inhibitors): include cardiovascular risk factors and whether patient has or is at high risk for MACE/VTE (FDA boxed warning documentation required on some plans for prescriber certification)
✓ Trikafta (elexacaftor/tezacaftor/ivacaftor): CFTR mutation genotyping result required — two copies of F508del or one F508del + responsive mutation; sweat chloride at baseline helpful

How to Appeal a CVS Caremark Prior Authorization Denial

If Caremark denies a PA, you have multiple appeal pathways. The denial letter (Explanation of Benefits or Coverage Determination) will specify the appeal type, deadline, and submission instructions. Don't ignore the deadline — most commercial plans allow 30–180 days from denial for the internal Level 1 appeal.

Step-by-step Caremark appeal process:

✓ 1. Read the denial reason precisely: the denial must cite the specific clinical policy or criterion that was not met; your appeal must directly address that criterion — not just resubmit the original documentation
✓ 2. Gather additional documentation: add objective data that was missing (lab values, disease severity scores, specialist notes, peer-reviewed literature)
✓ 3. Write a structured appeal letter: open with patient identifiers and the one-sentence request; cite the Caremark clinical policy number from the denial letter and explain point-by-point why your patient meets each criterion
✓ 4. Request peer-to-peer review: call Caremark's peer-to-peer line (usually listed on the denial letter or at 1-800-294-5979 for specialty); physician-to-physician reviews overturn 40–60% of Caremark specialty drug denials when the prescriber is prepared with guideline citations
✓ 5. If internal appeal fails: request external independent review through the plan (required under ACA for most commercial plans); external reviewers overturn about 40% of Caremark denials — don't stop at the internal appeal
✓ 6. State Insurance Commissioner: if external review fails or is unavailable, most states provide an Insurance Commissioner complaint pathway

CVS Caremark Medicare Part D PA Process

For Medicare Part D plans that use CVS Caremark as their PBM, the PA process follows CMS-mandated timelines: 72 hours for standard requests and 24 hours for expedited (urgent) requests. Medicare beneficiaries have additional appeal rights under CMS, including a fast track to an Independent Review Entity (IRE) if their plan's internal appeal is denied.

Key Medicare Part D differences at Caremark:

✓ Coverage determination (initial PA): must be decided in 72 hours standard / 24 hours expedited
✓ Redetermination (Level 1 appeal): 7 calendar days standard / 72 hours expedited
✓ Reconsideration by IRE (Level 2): 7 calendar days standard / 72 hours expedited
✓ GLP-1 coverage on Medicare Part D: Wegovy is covered only for cardiovascular disease indication (BMI ≥27 + established CVD, per SELECT trial CMS determination) — document CV history explicitly
✓ Part D step therapy: CMS rules allow Part D plans to require step therapy, but exceptions must be granted for contraindicated steps or documented prior failures; use the CMS exception language in your request

RxCheckUp and CVS Caremark PAs

RxCheckUp integrates CVS Caremark's current clinical review criteria and generates letters of medical necessity pre-formatted to address each criterion point-by-point. For Caremark-processed plans, the system identifies the plan-specific formulary tier, step-therapy requirements, and relevant clinical policy number — so your LMN reads directly back to the reviewer's checklist.

For appeals, RxCheckUp reads the denial reason code and drafts a targeted rebuttal that cites the specific Caremark policy language, adds the missing clinical evidence, and includes peer-reviewed literature — reducing the average appeal turnaround from days to under one hour.